Regeneron: Phase III Success In Skin Cancer For Libtayo
Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...
BioSpace6d
Where Keytruda Failed, Regeneron Touts Phase III Skin Cancer Win for Libtayo
The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which ...
PMLiVE5d
Regeneron shares positive phase 3 results for Libtayo in high-risk skin cancer
Regeneron recently presented five-years results from the phase 3 EMPOWER-Lung 1 trial of Libtayo as a first-line treatment ...
Pharmabiz5d
Regeneron announces adjuvant Libtayo significantly improves DFS after surgery in high-risk CSCC in phase 3 trial
Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...
Regeneron Buy Rating Supported by Eylea HD Launch, Dupixent Expansion, and Libtayo Success
Morgan Stanley analyst Terence Flynn maintained a Buy rating on Regeneron (REGN – Research Report) yesterday and set a price target of ...
The American Journal of Managed Care2d
Adjuvant Cemiplimab Significantly Improves Disease-Free Survival in High-Risk Skin Cancer
Cemiplimab significantly reduced the risk of recurrence or death in patients with high-risk cutaneous squamous cell carcinoma ...
Healio6d
Cemiplimab extends DFS in high-risk cutaneous squamous cell carcinoma
Adjuvant cemiplimab prolonged DFS compared with placebo for certain patients with cutaneous squamous cell carcinoma, ...
pharmaphorum3d
ESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytruda
Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...
pharmaphorum1d
Sanofi's immunotherapy Libtayo gets FDA approval in first line lung cancer
Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...